Ad
related to: myriad genetics- Genomic Solutions
Our Genomic Sequencing Solutions
For Businesses.
- Provider Solutions
At-Home Healthcare Solutions.
To Integrate To Your Care Program.
- Request a Demo
We're Happy To Answer Any Questions
& Ease Any Concerns You May Have.
- Employer Solutions
Employee At-Home Wellness Solutions
Improve Your Workforce Health.
- Genomic Solutions
Search results
Myriad Genetics director Lee Nisley sells $156,860 in company stock By Investing.com
Investing.com· 5 days agoFollowing the sale, Nisley still retains a significant stake in the company, owning 66,650 shares of...
Amalgamated Bank Buys 692 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)
ETF DAILY NEWS· 3 days agoAmalgamated Bank lifted its stake in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 2.2% in the 4th quarter, according to the company in its most ...
Myriad Genetics CEO Paul J. Diaz sells shares worth over $5.7 million By Investing.com
Investing.com· 5 days agoPaul J. Diaz, the President and CEO of Myriad Genetics Inc. (NASDAQ:MYGN), has recently sold a...
Insider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)
GuruFocus.com via Yahoo Finance· 5 days agoOn May 15, 2024, Paul Diaz, President and Chief Executive Officer of Myriad Genetics Inc...
Top Research Reports for Microsoft, Eli Lilly & Costco
Zacks via Yahoo Finance· 3 days agoToday's Research Daily features new research reports on 16 major stocks, including Microsoft...
Almost 1 in 2 Americans feel they’ve lost time to poor mental health, survey says. It’s worse for...
Fortune via Yahoo Finance· 6 days agoAmong people diagnosed with depression and/or anxiety, this percentage nearly doubles to 78%. That’s...
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
Zacks via Yahoo Finance· 5 days agoIts collaboration with Element Biosciences promises to deliver unprecedented insights across various...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoChicago, May 16, 2024 (GLOBE NEWSWIRE) -- Cancer Biomarkers market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029 according to a
